Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCC – Targeted Oncology
Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCCTargeted OncologyAn extension in overall survival (OS) with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) has completely changed the standard of care for pa… Continue reading
